Search information
Ownership
Exclude Filing Types
Kestra Medical Technologies, LTD.
Companies
Tables in SEC filings
Source
Six Months Ended October 31, | Fiscal Year Ended April 30, | |||||||||||||||
(in thousands, except share and per share amounts) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
Provision for income taxes (1) | 15 | 37 | 24 | 15 | ||||||||||||
Net loss and comprehensive loss | $ | (40,944) | $ | (50,217) | $ | (94,120) | $ | (84,238) | ||||||||
Net loss attributable to non-controlling interest | (692) | — | — | — | ||||||||||||
Net loss and comprehensive loss attributable to West Affum Intermediate Holdings Corp. | (40,252) | (50,217) | (94,120) | (84,238) | ||||||||||||
Less: Undeclared preferred stock dividends | 5,706 | 2,915 | 6,721 | 2,499 | ||||||||||||
Net loss attributable to common stockholder, basic and diluted | $ | (45,958) | $ | (53,132) | $ | (100,841) | $ | (86,737) | ||||||||
Net loss per share attributable to common stockholder, basic and diluted | $ | (434) | $ | (502) | $ | (953) | $ | (820) | ||||||||
Weighted-average shares of common stock, basic and diluted | 105,808 | 105,808 | 105,808 | 105,808 | ||||||||||||
Pro forma net loss per share attributable to common shareholders, basic and diluted (1)(2) | (1.09) | (2.65) | ||||||||||||||
Pro forma weighted-average common shares, basic and diluted (1)(2) | 37,640,470 | 37,640,470 | ||||||||||||||
October 31, 2024 | April 30, 2024 | |||||||
Bonuses and commissions | $ | 4,424 | $ | 4,291 | ||||
Other expenses | 4,043 | 2,651 | ||||||
Vacation | 1,982 | 1,903 | ||||||
Payroll and payroll taxes | 336 | 234 | ||||||
Deferred revenue | 330 | — | ||||||
Accrued liabilities | $ | 11,115 | $ | 9,079 | ||||
2024 | 2023 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 8,249 | $ | 14,810 | ||||
Accounts receivable | 1,998 | — | ||||||
Disposable medical equipment supplies | 3,290 | 2,113 | ||||||
Prepaid expenses and other current assets | 1,370 | 1,500 | ||||||
Total current assets | 14,907 | 18,423 | ||||||
Right-of-use assets | 2,286 | 1,278 | ||||||
Deposits | 1,710 | 2,642 | ||||||
Restricted cash | 334 | 512 | ||||||
Property and equipment, net | 26,105 | 15,445 | ||||||
Other long-term assets | 607 | 356 | ||||||
Total assets | $ | 45,949 | $ | 38,656 | ||||
Liabilities, Redeemable Preferred Stock and Stockholder’s Deficit | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 23,892 | $ | 6,162 | ||||
Accrued liabilities | 9,079 | 8,765 | ||||||
Operating lease liabilities, current portion | — | 1,366 | ||||||
Long-term debt, current portion | — | 20,446 | ||||||
Total current liabilities | 32,971 | 36,739 | ||||||
Operating lease liabilities, net of current portion | 2,633 | — | ||||||
Other long-term liabilities | 76 | 63 | ||||||
Long-term debt, net | 42,536 | 17,322 | ||||||
Total liabilities | 78,216 | 54,124 | ||||||
Commitments and contingencies (Note 13) | ||||||||
Redeemable preferred stock, $0.01 par value; 5,000,000 shares authorized, 177,110 shares issued and outstanding | 177,110 | 102,110 | ||||||
Stockholder’s deficit | ||||||||
Common stock, $0.01 par value; 5,000,000 shares authorized; 105,808 shares issued and outstanding | 1 | 1 | ||||||
Additional paid-in capital | 197,057 | 194,736 | ||||||
Accumulated deficit | (406,435) | (312,315) | ||||||
Total stockholder’s deficit | (209,377) | (117,578) | ||||||
Total liabilities and stockholder’s deficit | $ | 45,949 | $ | 38,656 | ||||
April 30, | ||||||||
2024 | 2023 | |||||||
U.S. operations | $ | (75,374) | $ | (62,739) | ||||
Foreign operations | (18,722) | (21,484) | ||||||
Net loss before provision for income taxes | $ | (94,096) | $ | (84,223) | ||||
Fiscal Year Ended April 30, | ||||||||
(in thousands) | 2024 | 2023 | ||||||
Net cash used in operating activities | $ | (72,235) | $ | (69,642) | ||||
Net cash used in investing activities | (12,229) | (15,461) | ||||||
Net cash provided by financing activities | 77,725 | 96,106 | ||||||
Increase (decrease) in cash, cash equivalents and restricted cash | $ | (6,739) | $ | 11,003 | ||||